Overcoming Barriers to Initiating or Intensifying Insulin Therapy: Best Practices for the Family Physician

Release date: April 11, 2019
Expiration date: April 11, 2020
Estimated time to complete activity: 1.0 hour(s)

 

FACULTY

Davida F. Kruger, MSN, APN-BC, BC-ADM
Certified Nurse Practitioner
Supervisor Nurse Practitioner
Henry Ford Health System
Division of Endocrinology, Diabetes and Bone Disorders
Detroit, Michigan

PROGRAM OVERVIEW

Although practitioners know poor glycemic control puts their patients at increased risk for developing diabetes complications, many delay insulin therapy. This program has been developed to aid family practice clinicians, who are at the frontline of care for these individuals. It will examine the safety, efficacy, and pharmacokinetic/pharmacodynamic (PK/PD) data of newer basal insulin analogs as compared to older insulins. In addition, our faculty will review clinical data on combinations of basal insulin with rapid-acting insulin and GLP-1 receptor agonists and provide updates on newer follow-on insulin therapies. The ultimate goal is to provide clinicians with the skills to provide patient-centered care in order to individualize therapy and improve patient satisfaction, adherence and quality of life (QOL).

TARGET AUDIENCE

This educational initiative has been designed for family practice and primary care providers (PCPs) involved in the management of patients with diabetes.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants will be able to:

  • Articulate clinical strategies for the timely initiation and modification, and intensification of insulin therapy to achieve glycemic control
  • Explain novel strategies to optimize insulin therapy in clinical practice to improve glucose control, reduce risk of weight gain and hypoglycemia, and increase patient access, acceptance and adherence
  • Utilize a patient-centered approach to individualize therapy and appropriately and effectively transition patients to insulin and insulin combinations
DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of April 11, 2019 through April 11, 2020, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

MEDIA

Internet

ACCREDITATION STATEMENT

Integrity Continuing Education is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or info@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Davida F. Kruger, MSN, APN-BC, BC-ADM
Advisory Boards: Abbott, Dexcom, Eli Lilly & Company, Intarcia, Janssen, Novo Nordisk, Sanofi Aventis,
Speakers Bureau: Abbott, AstraZeneca, BI Lilly, Dexcom, InsuletJanssen, Lilly, Novo Nordisk, Valeritas,
Grants/Research Support Committees: Abbott, AstraZeneca, Dexcom, Eli Lilly, Hemsley Foundation, Lexicom, Novo Nordisk,
Stock: Dexcom

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi US and Novo Nordisk do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10

Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10

Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc.

SUPPORTER ACKNOWLEDGEMENT

Supported by educational grants from Sanofi US and Novo Nordisk.

Continue to Pretest